MSN Labs unveils generic Favipiravir under brand name Favilow 800 mg at Rs 144 per tablet
New Delhi: MSN Laboratories on Wednesday said it has launched the generic version of antiviral drug Favipiravir in 800 mg strength for treating mild and moderate COVID-19 patients.
The company''s drug to be sold under the brand name ''Favilow 800 mg'' is priced at Rs 144 per tablet and will be available across pharmacies, MSN Laboratories said in a statement.
"In the light of increasing COVID-19 cases in India, affordable treatment options are the need of the hour to flatten the curve. We are sure that our product Favilow 800 would help support the nation''s efforts in overcoming the COVID crisis," MSN Group Chairman and Managing Director MSN Reddy said.
Read also: Fujifilm to restart clinical trial of Avigan for COVID-19 treatment: Report
The company had launched the drug in the strengths of 200 mg and 400 mg in August 2020, the statement said.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.